Regulatory PathRegulatory requirements compared

Active substance

Tofersen

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
Qalsody6.7 mg/mlSolution for injection · Intrathecal use1 VialSAR 98211.15NCE · PrescriptionBiogen Idec B.V-NatherlandValid

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
QALSODY100MG/15ML (6.7MG/ML)solution · intrathecalBIOGEN MAPrescription25 Apr 2023

EMA European Union — centrally authorised medicines

Qalsody Biogen Netherlands B.V. · Authorised · authorised 29 May 2024 · ATC N07XX22

Therapeutic indication (EMA)

Qalsody is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
QALSODY02555735100 MG / 15 MLSOLUTION · INTRATHECALBIOGEN CANADA INC

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.